MedPath

Oncologic Outcomes and Toxicities of Salvage Treatment in Patients With Locoregionally Recurrent Breast Cancer

Recruiting
Conditions
Breast Cancer
Interventions
Other: Salvage treatment (surgery and/or radiation therapy)
Registration Number
NCT05933733
Lead Sponsor
Samsung Medical Center
Brief Summary

The purpose of this study is to evaluate clinical outcomes and adverse events of salvage treatment for locoregional recurrence of breast cancer.

The main questions it aims to answer are:

* Clinical outcomes after salvage treatment for locoregional recurrence

* Adverse events and quality of life after salvage treatment for locoregional recurrence

* Patient characteristics and treatment specifics which are related to the clinical outcomes and/or adverse events

* Molecular signature associated with treatment resistance

Participants will be assessed by multi-dimensional methods during and after radiation therapy:

* Assessment for the disease status (disease-free or recurrence) including physical and radiologic examination

* Assessment for the adverse events according to CTCAE version 5.0

* Assessment for the molecular signature using residual tissue after pathologic diagnosis

* Assessment for the quality of life using questionnaires (BREAST-Q)

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
190
Inclusion Criteria
  • Female patients with age 18 to 100.
  • Previous standard definitive treatment for initial breast cancer
  • Locoregional recurrence without distant metastasis
  • Planned salvage treatment for locoregional recurrence
  • Informed consent of the participant
Exclusion Criteria
  • Not anticipated for complying the study protocol

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Salvage treatment after locoregional recurrenceSalvage treatment (surgery and/or radiation therapy)Participants who previously completed standard treatment for breast cancer and experienced locoregional recurrence alone will be undergo salvage treatment including surgery and/or radiation therapy.
Primary Outcome Measures
NameTimeMethod
Progression-free survival5 years from the initiation of the salvage therapy

The event for progression-free survival was defined as any disease progression or breast cancer-related death.

Rate of adverse events5 years from the initiation of the salvage therapy

Adverse events related to the salvage therapy will be reported and incidence rate will be calculated.

Secondary Outcome Measures
NameTimeMethod
Cancer-specific survival5 years from the initiation of the salvage therapy

The event for cancer-specific survival was defined as death of the participant related to the breast cancer.

Breast cosmesis5 years from the initiation of the salvage therapy

Cosmesis of the breast will be evaluated according to Harvard/National Surgical Adjuvant Breast and Bowel Project (NSABP)/Radiation Therapy Oncology Group (RTOG) Breast Cosmesis grading scale. This is a 4-point scale (Excellent, Good, Fair, and Poor), and evaluated by the clinicians.

Locoregional failure rate5 years from the initiation of the salvage therapy

The event for locoregional failure rate was defined as recurrence in breast / chest wall or regional lymph node area.

Quality of life (BREAST-Q)5 years from the initiation of the salvage therapy

Quality of life of the participants will be evaluated according to the BREAST-Q™ questionnaires. Higher Q-Score indicates better quality of life.

Trial Locations

Locations (1)

Samsung Medical Center

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath